Recombinant Rat ADRBK1 Protein
Cat.No. : | ADRBK1-546R |
Product Overview : | Recombinant Rat ADRBK1 full length or partial length protein was expressed. |
- Specification
- Gene Information
- Related Products
Source : | Mammalian Cells |
Species : | Rat |
Tag : | His |
Form : | Liquid or lyophilized powder |
Endotoxin : | < 1.0 EU per μg of the protein as determined by the LAL method. |
Purity : | >80% |
Notes : | This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications. |
Storage : | Store it at +4 ºC for short term. For long term storage, store it at -20 ºC~-80 ºC. |
Storage Buffer : | PBS buffer |
Gene Name : | Adrbk1 adrenergic, beta, receptor kinase 1 [ Rattus norvegicus ] |
Official Symbol : | ADRBK1 |
Gene ID : | 25238 |
mRNA Refseq : | NM_012776.1 |
Protein Refseq : | NP_036908.1 |
MIM : | |
UniProt ID : | P26817 |
Products Types
◆ Recombinant Protein | ||
ADRBK1-2437H | Recombinant Human ADRBK1 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADRBK1-978H | Recombinant Human ADRBK1 protein(Met1-Leu689), His&GST-tagged | +Inquiry |
ADRBK1-202R | Recombinant Rat ADRBK1 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADRBK1-152H | Recombinant Human ADRBK1 | +Inquiry |
ADRBK1-383H | Active Recombinant Human ADRBK1 Protein, GST-tagged | +Inquiry |
◆ Lysates | ||
ADRBK1-625HCL | Recombinant Human ADRBK1 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (8)
Ask a questionADRBK1 inhibitors have shown potential as a treatment for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) in preclinical studies. ADRBK1 is involved in the regulation of airway tone and smooth muscle contraction, and ADRBK1 inhibition has been shown to improve airway function and reduce inflammation in preclinical models of asthma and COPD. However, more research is needed to determine the efficacy and safety of ADRBK1 inhibitors in human clinical trials for these indications.
Yes, several genetic mutations have been identified that affect ADRBK1 proteins, leading to functional alterations and disease susceptibility. For example, a common variant in the ADRBK1 gene, known as the ADRBK1 A>G polymorphism, has been associated with increased risk of heart failure, hypertension, and other cardiovascular diseases. Other studies have linked mutations in ADRBK1 with conditions like asthma, diabetes, and Alzheimer's disease, although the exact mechanisms by which these mutations contribute to pathology are not fully understood.
Like any drug or therapeutic intervention, modulating ADRBK1 activity or expression carries potential risks and side effects. For example, blocking ADRBK1 activity could potentially lead to excessive receptor activation and signaling, causing unintended consequences and potential toxicity. Conversely, enhancing ADRBK1 activity could lead to receptor desensitization and decreased responsiveness to ligands, which could impair normal physiological processes. Therefore, the safety and efficacy of ADRBK1-targeted therapies must be carefully evaluated in preclinical and clinical studies before being implemented in the clinic.
ADRBK1, also known as beta-adrenergic receptor kinase 1, plays a crucial role in regulating signaling pathways in the cardiovascular system. It is involved in the regulation of cardiac function, blood pressure, and vascular tone. ADRBK1 is responsible for phosphorylating and desensitizing beta-adrenergic receptors, which are involved in the regulation of heart rate, contractility, and vascular tone. ADRBK1 inhibition has been shown to improve cardiac function, reduce blood pressure, and mitigate the effects of heart failure in preclinical studies. However, more research is needed to fully understand the effects of ADRBK1 inhibition on the cardiovascular system and to determine the safety and efficacy of these therapies in human clinical trials.
ADRBK1 proteins continue to be an active area of research, with ongoing investigations exploring their roles in various disease processes and their potential as therapeutic targets. Some current research areas include developing more selective and potent ADRBK1 inhibitors, exploring the effects of ADRBK1 polymorphisms on disease susceptibility and drug response, and investigating the complex signaling pathways that involve ADRBK1 in different tissues and cell types. Additionally, preclinical and clinical studies are continuing to evaluate the safety and efficacy of ADRBK1-targeted therapies in various disease settings.
There are currently no ADRBK1 inhibitors approved for clinical use. However, several compounds are being developed as potential ADRBK1 inhibitors for use in the treatment of cardiovascular and metabolic diseases, as well as anxiety disorders and cancer. These compounds are in various stages of preclinical and clinical development, and more research is needed to determine their safety and efficacy in human clinical trials.
Dysregulation of ADRBK1 activity has been implicated in several disease processes, including cardiovascular disease, immune dysfunction, and cancer. In cardiovascular disease, elevated levels of ADRBK1 have been associated with impaired cardiac function, while decreased levels have been linked to hypertension and myocardial infarction. In immune dysfunction, ADRBK1 contributes to the development of inflammatory responses, and increased activity has been observed in conditions like asthma, rheumatoid arthritis, and sepsis. In cancer, ADRBK1 has been shown to promote tumor growth and metastasis.
Yes, there are several drugs that target ADRBK1 proteins. These include small molecule inhibitors that block ADRBK1 activity and prevent receptor desensitization, as well as compounds that modulate ADRBK1 expression or activity indirectly. Some of these drugs have shown promise in preclinical and clinical studies for treating conditions like heart failure, hypertension, and asthma.
Customer Reviews (4)
Write a reviewThe bands of proteins in the Western Blotting experiment were very clear
The ADRBK1 protein is of exceptional quality and is precisely what I need for my experimental purposes.
With confidence in the protein's quality and the assistance provided by the supplier, I believe this is the ideal protein to meet my experimental needs.
I am confident that it will provide reliable and consistent results.
Ask a Question for All ADRBK1 Products
Required fields are marked with *
My Review for All ADRBK1 Products
Required fields are marked with *
Inquiry Basket